Last Update: May 31, 2023
Regulatory Post-Marketing Surveillance(PMS) Study for Lucentis®(Ranibizumab) in Patients With Retinopathy of Prematurity Identifier:
Novartis Reference Number:CRFB002HKR01
All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.

Study Description

This study is an open-labeled, multicenter, single arm, observational post-marketing surveillance study under routine clinical practice with no mandated treatments, visits or assessments.

Retinopathy of Prematurity
Jun 22, 2022
Jan 12, 2025
- 10 Years (Child)




There is no treatment allocation. Patients administered Lucentis by prescription will be enrolled.

Eligibility Criteria

Inclusion Criteria:

Premature infants with retinopathy of prematurity (ROP)
Patients (infants) prescribed with Lucentis® injection according to the product approval information in the Republic of Korea
In the case that the legal guardian of the patient (infant) provided a written consent to participate in this study

Exclusion Criteria:

In the case that the legal guardian of the patient (infant) does not want participation in this study

In the case that it falls under any of the contraindications listed in local prescribing information of Lucentis® injection

Patients with hypersensitivity to the active substance or to any of the excipients
Patients with an active or suspected ocular or periocular infection.
Patients with active intraocular inflammation

Study Location

Novartis Investigative Site


Daegu,Dalseo Gu,42602,Korea, Republic of

Novartis Investigative Site


Seoul,06351,Korea, Republic of

Worldwide Contacts

If the location of your choosing does not feature any contact detail, please reach out using the information below.

Novartis Pharmaceuticals


Novartis Pharmaceuticals